<DOC>
	<DOCNO>NCT02085135</DOCNO>
	<brief_summary>This Phase 3 study design evaluate safety tolerability two titration schedule ALKS 5461 .</brief_summary>
	<brief_title>A Study Different Titration Schedules ALKS 5461 Adults With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Body mass index 1840 kg/m2 Have diagnosis MDD Have current major depressive episode ( MDE ) last 8 week 24 month Have treat adequate dose approve antidepressant current MDE least 8 week Have inadequate response current antidepressant treatment Agree use approve method birth control duration study Additional criterion may apply Currently pregnant breastfeed History current infection Hepatitis B Virus , Hepatitis C Virus Human Immunodeficiency Virus ( HIV ) Have experience hallucination , delusion , psychotic symptom current MDE Have use opioid agonist ( eg , codeine , oxycodone , tramadol , morphine ) opioid antagonist ( eg , naloxone , naltrexone ) within 14 day Have receive electroconvulsive therapy treatment within last 5 year Have attempt suicide within past 2 year Have history intolerance , allergy , hypersensitivity buprenorphine opioid antagonist ( eg , naltrexone , naloxone ) Have significant blood loss blood donation 60 day screen Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 5461</keyword>
	<keyword>samidorphan</keyword>
	<keyword>buprenorphine</keyword>
</DOC>